Loading
A phase 1/2 trial of Rituximab, Glofitamab, Obinutuzumab in hodgkin lymphoma and non-hodgkin lymphoma, run by Bristol-Myers Squibb, now recruiting.
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas is a phase 1/2 interventional study registered as NCT06090539 by Bristol-Myers Squibb, with 460 participants planned, started 2023-12-29 and due to reach its primary completion in 2027-10-28. Interventions recorded: BMS-986458, Rituximab, Glofitamab/Obinutuzumab, Mosunetuzumab, Epcoritamab. Conditions listed: Relapsed/Refractory Non-Hodgkin Lymphoma. No results are recorded here; the registry entry is the source.
Shares Mosunetuzumab, Epcoritamab, Glofitamab, Obinutuzumab.
Shares Golcadomide, Obinutuzumab, Rituximab, Bristol Myers Squibb.
Shares Glofitamab, Obinutuzumab, Rituximab, Hodgkin lymphoma.
Shares Mosunetuzumab, Glofitamab, Obinutuzumab, Non-Hodgkin lymphoma (all types).
Shares Mosunetuzumab, Epcoritamab, Glofitamab, Obinutuzumab.
Shares Golcadomide, Rituximab, Bristol Myers Squibb, Non-Hodgkin lymphoma (all types).
Shares Mosunetuzumab, Rituximab, Hodgkin lymphoma, Non-Hodgkin lymphoma (all types).
Shares Glofitamab, Obinutuzumab, Rituximab, Non-Hodgkin lymphoma (all types).